Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title
14 Dec 2007 Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation
13 Dec 2007 Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
13 Dec 2007 Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11 Dec 2007 Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight
11 Dec 2007 ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data
11 Dec 2007 Medicis and Revance Announce Strategic Collaboration
10 Dec 2007 ZymoGenetics Presents Positive Interim Phase 1 Results for IL-21 in Combination with Rituxan(R) in B Cell Lymphoma
10 Dec 2007 CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10 Dec 2007 Gloucester Pharmaceuticals Reports Clinically Significant Responses in Pivotal Trial of Romidepsin for Cutaneous T-cell Lymphoma at the 2007 American Society of Hematology (ASH) Annual Meeting
09 Dec 2007 Nuvelo Phase 3 SONOMA-2 Trial Shows Alfimeprase has the Potential to Restore Catheter Function
08 Dec 2007 Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
07 Dec 2007 Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
07 Dec 2007 Submission of Marketing Authorisation Application for Dapoxetine in Europe
07 Dec 2007 Access Pharmaceuticals Demonstrates Ability To Significantly Reduce Glucose Levels in Pre-clinical Testing of
06 Dec 2007 Ipsen submits a Biologics License Application (BLA) in cervical dystonia to the FDA for Dysport(R)
06 Dec 2007 Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA
05 Dec 2007 Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
05 Dec 2007 GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and Fibrinogen
04 Dec 2007 ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
03 Dec 2007 Early Treatment with COPAXONE® Demonstrated Robust Protection against Progression to Clinically Definite Multiple Sclerosis in the PreCISe Study
03 Dec 2007 Fibrex Medical Completes Enrolment of Phase II Trial of Treatment for
03 Dec 2007 Clal Biotechnology Industries and Teva Pharmaceuticals Solidify their Collaboration for Final Stage Development of Type 1 Diabetes Drug
03 Dec 2007 BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
03 Dec 2007 Buck Institute and Neurobiological Technologies, Inc. Partner to Develop Treatment for Huntington's Disease
30 Nov 2007 Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in Breast Cancer Patients
28 Nov 2007 Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
28 Nov 2007 Immutep Announces Positive Interim Results From a Study of Immufact(R) IMP321 in Metastatic Breast Cancer
28 Nov 2007 Zosano Pharma, Inc. Closes Enrollment in Phase 2 Trial
28 Nov 2007 Aida Announces Completion of Anti-Cancer Drug Phase Two Testing
27 Nov 2007 Eurand Completes Bioavailability Study of Zentase(TM)
27 Nov 2007 BioMarin Files Investigational New Drug Application for PEG-PAL for the Treatment of PKU
26 Nov 2007 SYGNIS AG and Dr. Reddy’s sign exclusive Supply Collaboration for AX200 in Stroke
26 Nov 2007 Maxygen Updates Status of MAXY-alpha Program
20 Nov 2007 New phase 2 study shows that liraglutide leads to significant weight loss in obese people
20 Nov 2007 Cardiome Initiates Phase 1 Study for GED-aPC
19 Nov 2007 Pacgen Initiates a Phase IIb Clinical Trial For PAC-113
19 Nov 2007 TransMolecular Reports Positive Phase 2 Data from Study of 131 Iodine Radiolabeled TM-601 in Recurrent Glioma
15 Nov 2007 FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
15 Nov 2007 Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
15 Nov 2007 PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
15 Nov 2007 FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing
15 Nov 2007 Oramed Pharmaceuticals Successfully Completes Animal Studies for Phase 1B Clinical Trials Of Its Oral Insulin Capsule
15 Nov 2007 FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing
13 Nov 2007 Insmed Advances Follow on Biologics Initiative
13 Nov 2007 Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
13 Nov 2007 Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
12 Nov 2007 Akela Pharma Announces Final Positive Results From Its Growth Hormone Releasing Hormone (GHRH) Phase II Trial
12 Nov 2007 DIREVO and Pfizer collaborate on therapeutic proteases
09 Nov 2007 Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
09 Nov 2007 PTH 1-34, Phase 2a Clinical Trials Initiated
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 301 - 350 of 1301

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Thrombopoiesis-Stimulating Agents (TPO)

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics